Risk of being unable to secure licensing revenue or agreements due to insufficient evaluations from potential partners
First written in FY2024. 1 of 2 entries say "Worsened", first in FY2025. Latest entry: FY2025.
Chordia Therapeutics moved to the "Worse" side of this theme in 2025.
0 other companies' latest entry also says "Worsened".
- FY2025WorsenedAnnual report
「As the license agreement with Ono Pharmaceutical referred to above has ended, we currently have no license agreement from which milestone revenue can be expected. We will therefore seek new license agreements with pharmaceutical companies in Japan and overseas; however, entering into a license agreement depends on the counterparty's assessment of our pipelines and its management decisions, so we may be unable to establish a licensing partnership at the timing we anticipate.」
Following termination of the CTX-177 agreement, the company currently has no license agreement from which milestone revenue can be expected, making the uncertainty surrounding new out-licensing more concrete. - FY2024First statedAnnual report
「There is a possibility that pharmaceutical companies may not sufficiently value the results of our research and development, or may not value them at the expected time due to delays in our research and development or the pipeline status of pharmaceutical companies being considered as potential licensees. There is also a possibility that, because the valuation by pharmaceutical companies may fall short of expectations, we may be unable to enter into agreements for upfront payments and other types of revenue described above at the amounts we anticipate, or may be unable to enter into a license agreement at all.」
The risk was disclosed that licensing agreements or revenue may not be realized at the expected timing or amount due to pipeline valuations, circumstances affecting potential partners and development delays.